BioVaxys Technology (FRA:5LB0) Total Current Assets: €0.87 Mil (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioVaxys Technology Total Current Assets?

BioVaxys Technology FRA:5LB0 Total Current Assets is €0.87 Mil as of Jul. 2025.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BioVaxys Technology's total current assets for the quarter that ended in Jul. 2025 was €0.87 Mil.

BioVaxys Technology  (FRA:5LB0) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BioVaxys Technology's Liquidation Value for the quarter that ended in Jul. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.003-3.147+0.75 * 0+0.5 * 0
=-3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology Total Current Assets Related Terms

BioVaxys Technology Total Current Assets Historical Data

* Premium members only.

The historical data trend for BioVaxys Technology's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology Total Current Assets Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Total Current Assets
Get a 7-Day Free Trial 1.97 0.61 0.53 0.08 0.87

BioVaxys Technology Quarterly Data
Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.87 0.86 0.70 0.87

BioVaxys Technology Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BioVaxys Technology's Total Current Assets for the fiscal year that ended in Oct. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.141+0.291+0+0.436
=0.87

BioVaxys Technology's Total Current Assets for the quarter that ended in Jul. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.003+0.305+0+0.56
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €0.87 Mil mean?
BioVaxys Technology (FRA:5LB0) has a Total Current Assets of €0.87 Mil as of Jul. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for BioVaxys Technology and its competitors.
Is BioVaxys Technology's Total Current Assets too high?
BioVaxys Technology's current Total Current Assets is €0.87 Mil.
How does BioVaxys Technology's Total Current Assets compare to BPTH and AZTR?
BioVaxys Technology's Total Current Assets of €0.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for BioVaxys Technology and its competitors. BioVaxys Technology's current Total Current Assets is €0.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current Total Current Assets of €0.87 Mil. The current Total Current Assets is €0.87 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current Total Current Assets is €0.87 Mil as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVaxys Technology Business Description

Other Exchanges BVAXF:USABIOV:Canada
Address 595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.